- Home
- HOWL vs QNCX Comparison
HOWL vs QNCX Comparison
Compare HOWL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOWL | QNCX |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 17.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HOWL | QNCX |
|---|---|---|
| Price | $0.42 | $17.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 931.2K | 66.0K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.40 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.08 |
| 52 Week High | $2.23 | $20.72 |
Technical Indicators
Market Signals| Indicator | HOWL | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 74.23 |
| Support Level | $0.40 | $16.23 |
| Resistance Level | $0.75 | $19.26 |
| Average True Range (ATR) | 0.04 | 1.25 |
| MACD | 0.01 | -0.52 |
| Stochastic Oscillator | 97.53 | 33.63 |
Price Performance
Historical ComparisonAbout HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.